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Abstract
Background: Chronic kidney disease with metabolic acidosis is common in older people, but the effectiveness of
oral sodium bicarbonate therapy in this group is unclear. We tested whether oral sodium bicarbonate provides net
health benefit for older people with advanced chronic kidney disease and serum bicarbonate concentrations < 22
mmol/L.
Methods: Pragmatic multicentre, parallel group, double-blind, placebo-controlled randomised trial. We recruited
adults aged ≥ 60 years with estimated glomerular filtration rate of < 30 mL/min/1.73 m2, not receiving dialysis, with
serum bicarbonate concentration < 22 mmol/L, from 27 nephrology and geriatric medicine departments in the UK.
Participants received oral sodium bicarbonate (up to 3 g/day) or matching placebo given for up to 2 years,
randomised in a 1:1 ratio. The primary outcome was between-group difference in the Short Physical Performance
Battery (SPPB) at 12 months, adjusted for baseline values, analysed by intention to treat. Secondary outcomes
included generic and disease-specific quality of life (EQ-5D and KDQoL tools), anthropometry, renal function, walk
distance, blood pressure, bone and vascular health markers, and incremental cost per quality-adjusted life year
gained.
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Results: We randomised 300 participants between May 2013 and February 2017, mean age 74 years, 86 (29%)
female. At 12 months, 116/152 (76%) participants allocated to bicarbonate and 104/148 (70%) allocated to placebo
were assessed; primary outcome data were available for 187 participants. We found no significant treatment effect
for the SPPB: bicarbonate arm 8.3 (SD 2.5) points, placebo arm 8.8 (SD 2.2) and adjusted treatment effect − 0.4 (95%
CI − 0.9 to 0.1, p = 0.15). We found no significant treatment effect for glomerular filtration rate (0.6 mL/min/1.73 m2,
95% CI − 0.8 to 2.0, p = 0.39). The bicarbonate arm showed higher costs and lower quality of life as measured by
the EQ-5D-3L tool over 1 year (£564 [95% CI £88 to £1154]); placebo dominated bicarbonate under all sensitivity
analyses. Adverse events were more frequent in those randomised to bicarbonate (457 versus 400).
Conclusions: Oral sodium bicarbonate did not improve physical function or renal function, increased adverse
events and is unlikely to be cost-effective for use by the UK NHS for this patient group.
Trial registration: European Clinical Trials Database (2011-005271-16) and ISRCTN09486651; registered 17 February
2012.
Keywords: Sodium bicarbonate, Renal insufficiency, chronic, Acidosis, Randomised controlled trial,
Background
Chronic kidney disease (CKD) becomes increasingly
common with older age, with approximately 2% of the
population aged 70 years and over suffering from ad-
vanced (estimated glomerular filtration rate [eGFR] < 30
mL/min/1.73 m2) chronic kidney disease [1]. Impaired
ability to excrete hydrogen ions means that advanced
CKD is accompanied by metabolic acidosis in approxi-
mately 20% of cases, with rates higher at lower levels of
renal function [2]. Metabolic acidosis has been associ-
ated in observational studies with a range of adverse
health outcomes in patients with CKD, including worse
cardiovascular health, lower bone mineral density and
increased fracture risk, impaired muscle function and
more rapid progression of kidney disease [3–8]. The ex-
tent to which acidosis causes these phenomena remains
unclear.
Oral sodium bicarbonate has been used for decades to
counteract metabolic acidosis. Few trials have tested
whether sodium bicarbonate is effective at preventing
adverse outcomes from advanced CKD, and is safe in
the context of increased sodium load, as opposed to
merely increasing the concentration of circulating bicar-
bonate. Two recent systematic reviews and meta-
analyses of small trials of moderate quality suggested a
modest beneficial effect on estimated GFR and serum bi-
carbonate, an uncertain effect on progression to end-
stage kidney disease and contrasting effects on blood
pressure (no effect in one review, and a small increase in
the risk of hypertension in the other), and found no data
on the effect of bicarbonate on physical function or
quality of life [9, 10]. The mean age of participants in in-
cluded trials was young, ranging from 41 to 65 years. So-
dium bicarbonate carries risks of gastrointestinal side
effects, the large tablets and large number of tablets re-
quired are awkward for patients to take long term, and
there are concerns that the sodium content might
increase blood pressure or circulatory overload. These
issues are of particular relevance for older people, who
make up the majority of people in the UK with advanced
kidney disease and are more likely to suffer side effects
due to coexisting multimorbidity and polypharmacy.
Current guidelines for the management of chronic kid-
ney disease recommend using oral sodium bicarbonate
to treat metabolic acidosis but acknowledge the dearth
of evidence in this area [11, 12].
A focus on single disease outcomes may not always be
appropriate for older people with multimorbidity; im-
provements in a single organ domain may be counterba-
lanced by harms in other systems. Older people
consistently rank physical function and quality of life as
the most important outcomes [13] and measurement of
these outcomes allows the impact of an intervention to
be integrated across multiple organ systems. The pri-
mary objective of the BiCARB trial was to determine
whether oral bicarbonate therapy improves physical
function compared to placebo in older people with CKD
and mild acidosis. The secondary objectives were to as-
sess the effect of bicarbonate supplementation on
health-related quality of life, biochemical markers of
CKD, bone and vascular health, adverse events and
healthcare costs.
Methods
Study design
We conducted a parallel group, double-blind, placebo-
controlled randomised trial. The trial was designed in re-
sponse to a commissioning brief issued by the National
Institute for Health Research (NIHR) Health Technology
Assessment board. We recruited participants from neph-
rology and geriatric medicine outpatients at 27 UK hos-
pitals. Ethical approval was granted by the East of
Scotland NHS Research Ethics Committee (approval 12/
ES/0023); the trial was also approved by the UK
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Medicines and Healthcare Regulatory Authority
(EudraCT number 2011-005271-16; Clinical Trial Au-
thorisation number 41692/0001/001-0001). The trial was
co-sponsored by the University of Dundee and NHS
Tayside (Tayside Academic Health Sciences Collabor-
ation). The trial was registered at www.isrctn.com
(ISRCTN09486651). The protocol has been published
[14].
Participants
Participants were eligible for inclusion if they were ≥ 60
years with advanced CKD (estimated GFR < 30 mL/min/
1.73 m2 by Modification of Diet in Renal Disease study
four variable (MDRD4) equation [15]), not receiving dia-
lysis, with serum bicarbonate concentrations < 22 mmol/
L. No lower limit on bicarbonate concentration was stip-
ulated. The MDRD4 equation was used as this was the
equation in common use in the UK at the time that the
trial was designed. We excluded participants if they were
currently taking bicarbonate (such participants could
however enter a 3-month washout period, after which
they became eligible), had a diagnosis of renal tubular
acidosis, were taking a bisphosphonate, were terminally
ill, could not give written informed consent, had uncon-
trolled hypertension (blood pressure > 150/90 despite
four or more antihypertensive agents) or decompensated
chronic heart failure, were participating in another clin-
ical trial, or were allergic to sodium bicarbonate tablets
or lactose (excipient in the tablets). All participants gave
written informed consent.
We relaxed the exclusion criteria for the trial part-way
through recruitment, both to improve slow recruitment
rates, in part influenced by the lack of equipoise
amongst clinicians and to better reflect current UK clin-
ical practice. We reduced the lower age limit from 65 to
60; we included patients taking calcium acetate or seve-
lamer; we included patients with blood pressure con-
trolled on home readings even if office blood pressure
was high, and we allowed those currently taking bicar-
bonate to undergo a 3-month washout period with as-
sessment of eligibility at the end of the washout period.
Randomisation and masking
We randomised participants using an interactive web-
based randomisation, drug assignment and inventory
management system (TRuST) run by the Health Inform-
atics Centre, University of Dundee. The system was run
independently from the research team to preserve allo-
cation concealment. We performed randomisation in a
1:1 ratio, stratified by site, and employed a minimisation
algorithm to balance male vs female sex, CKD eGFR cat-
egory 4 vs category 5, and age < 75 years versus ≥ 75
years. We allocated study medication bottles to partici-
pants (one bottle per month) with either 500mg sodium
bicarbonate tablets or matching placebo tablets; we allo-
cated bottles using identification numbers generated by
the TRuST randomisation system, and bottles carried no
external indication to identify to which trial arm partici-
pants were allocated. Participants, researchers and clin-
ical teams and researchers including the statistician
remained masked to treatment allocation until after
completion of the main trial analysis.
Trial intervention and comparator
Active and placebo tablets were manufactured and bot-
tled by Legosan AB (Kumla, Sweden). For the first
3 months of participation, we asked participants to take
one tablet three times daily (i.e. 500 mg of sodium bicar-
bonate or placebo three times a day). We measured
serum bicarbonate concentration at the 3-month visit to
guide dose titration. If bicarbonate was < 22mmol/L, we
asked participants to increase their study medication to
two tablets three times a day (i.e. 1 g of sodium bicar-
bonate or placebo three times a day). If bicarbonate was
≥ 22mmol/L, we asked participants to continue taking
one tablet three times a day for the remainder of the
trial. Although higher doses of bicarbonate have been
used in some previous trials [9], we selected this dose to
reflect current UK clinical practice in the treatment of
acidosis; we judged that higher doses would be poorly
tolerated by older people on multiple medications. No
trial-specific dietary advice beyond usual care was given,
and no specific recommendations on management of
low serum bicarbonate concentrations were given to
study physicians.
Outcomes
We measured outcomes at baseline and 3, 6, 12 and 24
months. The primary outcome was the between-group
difference in the Short Physical Performance Battery
(SPPB) at 12 months, adjusted for baseline values. The
SPPB is a 12-point measure of lower limb strength and
balance, with higher values denoting better function,
that predicts future disability, need for care and death
[16–18]. The minimum clinically important difference
has been derived for the measure [16].
Secondary outcome measures were generic (EuroQoL
EQ-5D-3L) [19] and disease-specific (Kidney Disease
Quality of Life) [20] health-related quality of life, anthro-
pometry (weight, mid-arm muscle circumference, triceps
skinfold thickness, mid-thigh circumference), physical
performance (6-min walk speed, grip strength) and renal
function (serum creatinine, cystatin C, and urinary albu-
min/creatinine ratio); markers of bone turnover and
mineral metabolism (serum calcium, phosphate, bone-
specific alkaline phosphatase, tartrate-resistant acid
phosphatase 5b, 25-hydroxyvitamin D and 1,25 dihy-
droxyvitamin D); vascular health (blood pressure, B-type
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natriuretic peptide and serum cholesterol); and relevant
markers, including haemoglobin, thyroid-stimulating
hormone and albumin. Originally planned substudies
examining arterial stiffness and bone mineral density
were discontinued due to very low recruitment rates.
We recorded all adverse events, including commence-
ment of renal replacement therapy (defined as the first
episode of haemodialysis, peritoneal dialysis or renal
transplantation). We recorded falls prospectively using
participant-completed fall diaries, and we measured ad-
herence by counting pills taken divided by the number
of pills expected to be taken. For the health economic
analysis, we collected information on health and social
care use using participant-completed questionnaires at
follow-up visits, and we combined these data with
health-related quality of life measures (EQ-5D-3L and
ICEpop CAPability measure for Older people [ICECAP-
O]) and a measure of global life satisfaction to derive the
incremental cost per quality-adjusted life year (QALY)
gained.
Statistical analysis
We based the original sample size calculation on the
ability to detect a 1-point difference in the primary out-
come (SPPB), a difference proposed as the minimum
clinically important difference (MCID) by previous in-
vestigators [16]. Previous work with older people has
shown a standard deviation of 2.6 for the SPPB [21]. To
detect a 1-point difference between groups at 12 months
with 90% power given this standard deviation would re-
quire 143 participants per group given a two-sided alpha
of 0.05. To ensure that the trial had sufficient power for
the key secondary outcome of health-related quality of
life, we also estimated the sample size required to detect
the MCID for the EQ-5D-3L measure. For the EQ-5D-
3L, we assumed a MCID of 0.074 based on previous data
[22]. To detect this change at a two-sided alpha of 0.05
and power of 90% power, assuming a SD of change of
0.2 as found in our previous studies [23, 24] would re-
quire 154 participants per group. Assuming a 10% loss
to follow-up every 6 months (based on previous medica-
tion trials in frail older people) [24], we estimated that
we would require 380 patients (190 per group) to detect
the MCID with 90% power for the primary outcome and
the EQ-5D-3L at 12 months.
We used a prespecified statistical analysis plan. All
analyses were by intention to treat using SAS v9.4 (SAS
Institute Inc., Cary, NC, USA). We analysed the primary
outcome (between-group difference in the SPPB at 12
months) using linear mixed models, adjusted for baseline
measurements, minimisation variables (age, sex and
CKD category) and a random effect variable for recruit-
ment site. We analysed secondary outcomes using re-
peated measures mixed models, including all participants
and including data from all available timepoints. Models
were adjusted for baseline values and the minimisation
variables. We conducted time-to-event analyses (time to
death, time to commencing renal replacement therapy)
using Cox proportional hazards models adjusted for mini-
misation variables. All participants were included in
these analyses, with participants censored at the point
of dropout or truncation of follow-up for those not
reaching the analysis endpoint before 24 months. For
all analyses, we took a two-sided p value of < 0.05 as
significant with no adjustment for multiple testing.
For the health economic analysis, we undertook a
cost-utility analysis which involved estimation of the
incremental costs and incremental effects (QALYs)
from a health and social care perspective. We used
UK sources for unit cost estimates for items of re-
source use [25, 26] but did not include costs of medi-
cations other than bicarbonate. We derived estimates
using generalised linear regression modelling, with ad-
justment for skewed data and for baseline differences
in cost, EQ-5D-3L and minimisation variables. We
used non-parametric bootstrap methods to calculate
confidence intervals around cost and QALY differ-
ences. We generated cost-effectiveness acceptability
curves to show the probability that bicarbonate ther-
apy was cost-effective for different values of willing-
ness to pay per additional QALY. We conducted a
series of sensitivity analyses, using different measures
of quality of life to derive QALYs, testing a range of
different assumptions on costs and using multiple im-
putation to account for missing data. Sensitivity ana-
lyses included analyses that included renal
replacement therapy costs assumed to be incurred
after dropout from the trial for those who started
renal replacement therapy but then discontinued trial
participation.
An independent Data Monitoring Committee (DMC)
met every 6 months to review unmasked reports. The
DMC examined trial safety, data quality and study con-
duct and provided advice to the Sponsor, Trial Steering
Committee (TSC) and funder on the appropriateness of
continuing the trial. No interim efficacy analyses were
planned or conducted. The independent TSC recom-
mended closure of recruitment to the trial after 300 par-
ticipants had been randomised, based on a review of
declining recruitment rates and informed by revised
sample size calculations that showed that a sample size
of 300 had 87% power to detect a 1-point difference in
the primary outcome of the short physical performance
battery. The independent TSC also recommended that
follow-up be truncated after the final 12-month (primary
outcome) visit for the last participant to facilitate earlier
dissemination of results. The decision to close the trial
to further recruitment was made by the trial funder.
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Results
We randomised 300 participants into the trial between 1
May 2013 and 28 February 2017. Figure 1 depicts the
flow of participants through the trial; the mean length of
follow-up per participant was 16.4 months (16.6 (SD 8.9)
months in the bicarbonate arm (median 24, IQR 12 to
24months) and 16.3 (SD 9.4) months in the placebo
arm (median 24, IQR 6 to 24months)). Data for the pri-
mary outcome analysis were available for 274 partici-
pants at baseline (140 in the bicarbonate arm and 134 in
the placebo arm) and for 187 participants at 12 months
(97 in the bicarbonate arm and 90 in the placebo arm).
One hundred sixty-one participants completed the full
24-month follow-up period. Loss to follow-up was due
to a combination of deaths and illness; most participants
who commenced dialysis chose to withdraw from the
trial due to the added burden of dialytic treatment, al-
though this was not mandated by the protocol. Twenty-
two participants had their follow-up truncated due to
termination of the trial.
Fig. 1 CONSORT diagram for participant flow through the trial
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Baseline details for randomised participants in both
arms of the trial are given in Table 1. Only four partici-
pants underwent the 3-month washout option prior to
randomisation. Adherence by tablet count was moderate:
73% (95% CI 67 to 78) in the bicarbonate arm and 73%
(95% CI 67 to 80) in the placebo arm. Forty-six of 152 par-
ticipants in the bicarbonate arm had a serum bicarbonate
concentration of < 22mmol/L and were uptitrated at the
3-month visit, compared to 83/148 in the placebo arm. A
modest but significant increase in serum bicarbonate con-
centration of 1.7 mmol/L (95% CI 1.0 to 2.4, p < 0.001)
was seen in the intervention arm compared to placebo at
3months; this difference attenuated with time and was no
longer significant by 24months, as shown in Fig. 2. During
the course of the trial, 18 participants in the placebo group
stopped taking study medication on the advice of the clin-
ical team in order to start taking prescribed sodium bicar-
bonate. These individuals were retained in follow-up and
analysed as per their initial randomised allocation.
There was no significant between-group difference in the
primary outcome (SPPB at 12months, adjusted for baseline
values, age, sex and CKD stage). The adjusted treatment ef-
fect was − 0.4 points (95% CI − 0.9 to 0.1, p = 0.15) (nega-
tive values indicate worse physical performance in the
intervention arm); analysis adjusted only for baseline SPPB
gave the same result. Multiple imputation to account for
missing data gave similar results (adjusted treatment effect
− 0.3 points, 95% CI − 1.0 to 0.3, p = 0.29), and repeated
measures analysis across the whole of trial follow-up gave a
treatment effect of − 0.6 points (95% CI − 1.0 to − 0.1, p =
0.02). The participants who were unable to perform the
SPPB at 12months had borderline lower baseline SPPB
scores, lower baseline grip strength and lower 6-min walk
distance in both the bicarbonate and placebo arms but had
similar baseline serum bicarbonate concentrations. Full de-
tails are given in Additional File 1.
We conducted prespecified subgroup analyses for the
primary outcome by age, sex, baseline eGFR category,
baseline serum bicarbonate concentration and baseline
SPPB score; results are given in Fig. 3. No significant treat-
ment by subgroup interactions were found. We conducted
a further pre-planned subgroup analysis, comparing the
primary outcome treatment effect for those with good ad-
herence to study medication (defined a priori as > 80%)
versus poorer adherence to study medication (defined a
priori as ≤ 80%). Those with good adherence showed an
adjusted treatment effect at 12months of − 0.6 (95% CI −
1.4 to 0.1; p = 0.07), compared to an adjusted treatment ef-
fect of 0.0 (95% CI − 0.7 to 0.7; p = 0.97) for those with
poorer adherence. The difference in treatment effects was
not significant (p for interaction = 0.27).
Adjusted treatment effects for secondary outcomes are
given in Table 2. A total of 66/300 (22%) of participants
commenced dialysis or underwent renal transplantation
during the trial, with no difference between the bicar-
bonate and placebo arms (33 vs 33; p = 1.0). Time to
event analysis showed no significant difference in the
risk of commencing renal replacement therapy (HR 1.22,
95% CI 0.74 to 2.02; p = 0.43) (values greater than 1 indi-
cate higher risk in the intervention arm), or for reaching
a composite outcome of time to either doubling of
serum creatinine, a 40% reduction in eGFR, or commen-
cing renal replacement therapy (HR 1.16, 95% CI 0.73 to
1.84; p = 0.53). More participants in the bicarbonate arm
reported at least one fall than in the placebo arm but
this did not reach significance (49 vs 39; p = 0.26); the
incident rate in each arm was not significantly different
(bicarbonate arm, 0.99 per year [95% CI 0.61 to 1.38];
placebo arm, 0.72 per year [95% CI 0.25 to 1.19]; p =
0.38). Median time to first fall amongst those who fell
was shorter in the bicarbonate arm (130 days vs 194
days). Cox proportional hazards modelling of time to
first fall, adjusted for age, sex and CKD category, showed
a HR of 1.43, 95% CI 0.94 to 2.20, p = 0.09. Fragility frac-
ture numbers were low: 5/152 in the bicarbonate arm
and 2/148 in the placebo arm.
Similar numbers of participants in each arm experi-
enced at least one adverse event (131/152 [86.1%] in the
bicarbonate arm vs 132/148 [89.1%] in the placebo arm;
p = 0.38). More adverse events were recorded in the bi-
carbonate arm than in the placebo arm (457 vs 400) with
an excess of events in the bicarbonate arm coded under
gastrointestinal (45 vs 25), musculoskeletal (28 vs 17),
cardiac (32 vs 19), nervous (24 vs 12) and respiratory (26
vs 14) systems. Full details are presented in Table 3. The
difference in cardiac events was driven by an excess of
myocardial infarction or acute coronary syndrome (10 vs
2), and not by a difference in decompensated heart fail-
ure (8 vs 10). Twenty-six deaths were recorded during
the trial, with similar numbers in the bicarbonate and
placebo arms (15 vs 11; p = 0.45). Time to event analysis
showed no significant difference in the risk of death be-
tween groups (HR 1.30, 95% CI 0.60 to 2.83; p = 0.51).
Cost-effectiveness analyses
In unadjusted analysis amongst complete cases, the
mean costs per participant over the first 12 months of
follow-up were £1234 amongst the bicarbonate group
(n = 97) and £807 amongst the placebo group (n = 79).
Table 4 shows the adjusted costs and QALYs for each
group for complete cases at 12 month and 24months,
and imputed cases with renal replacement costs in-
cluded. Costs were significantly higher amongst patients
who received bicarbonate, and QALYs were significantly
lower. The only exception to this was the imputed ana-
lysis, where cost differences were no longer significant.
The robustness of these analyses was assessed using dif-
ferent acquisition cost estimates for bicarbonate therapy
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and inpatient stays, together with different estimates of
benefit (ICECAP-O measure and global life satisfaction).
Figure 4 shows the scatterplot and the associated cost-
effectiveness acceptability curves for these analyses.
Without including renal replacement costs, there is al-
most zero probability of the intervention being cost-
effective at conventional thresholds of willingness to pay.
With the inclusion of renal replacement costs, the prob-
ability that bicarbonate is cost-effective is no higher than
40%, and at the value of £30,000 per QALY convention-
ally used in the UK as a cost-effectiveness threshold, the
probability is 14%. Across the 24-month follow-up,
slightly more participants had at least one EQ-5D meas-
ure missing in the placebo group than in the bicarbonate
group (45% vs 36%) and slightly more participants had
Table 1 Baseline characteristics of randomised participants (n =
300)
Sodium bicarbonate
(n = 152)
Placebo
(n = 148)
Mean age (years) (SD) 73.9 (7.6) 74.0 (6.6)
Age 60–64 (%) 13 (8.6) 13 (8.8)
Age 65–69 (%) 44 (28.9) 22 (14.9)
Age 70–74 (%) 23 (15.1) 44 (29.7)
Age 75–79 (%) 30 (19.7) 37 (25.0)
Age 80–84 (%) 32 (21.1) 24 (16.2)
Age 85 and over (%) 10 (6.6) 8 (5.4)
Female sex (%) 42 (27.6) 44 (29.7)
Ethnicity
White (%) 144 (94.7) 143 (96.6)
East Asian (%) 0 (0) 1 (0.7)
Black (%) 1 (0.7) 0 (0)
South Asian (%) 4 (2.6) 2 (1.4)
Hispanic (%) 1 (0.7) 0 (0)
Other (%) 2 (1.3) 2 (1.4)
Cause of renal dysfunction*
Hypertension (%) 37 (24.3) 40 (27.0)
Diabetes mellitus (%) 23 (15.1) 23 (15.5)
Glomerulonephritis (%) 9 (5.9) 11 (7.4)
Polycystic kidney disease (%) 11 (7.2) 9 (6.1)
Vascular disease (%) 19 (12.5) 21 (14.2)
Other (%) 52 (34.2) 63 (42.6)
Not known (%) 31 (20.4) 22 (14.9)
Cardiovascular comorbidity
Hypertension (%) 135 (88.8) 129 (87.2)
Diabetes mellitus (%) 54 (35.5) 47 (31.8)
Ischaemic heart disease (%) 26 (17.1) 31 (20.9)
Stroke (%) 16 (10.5) 12 (8.1)
Heart failure (%) 19 (12.5) 5 (3.4)
Peripheral vascular disease (%) 14 (9.2) 10 (6.8)
Previous fragility fracture (%) 2 (1.3) 5 (3.4)
Mean number of medications (SD) 8.2 (3.7) 7.9 (3.3)
Medication use:
ACEi/ARB (%) 105 (69.1) 91 (61.5)
Phosphate binder (%) 32 (21.1) 28 (18.9)
Activated vitamin D (%) 77 (50.7) 73 (49.3)
Erythropoietin (%) 89 (58.6) 106 (71.6)
Iron (%) 60 (39.5) 51 (34.5)
Mean eGFR (mL/min/1.73 m2) (SD) 19.7 (6.5) 18.2 (6.4)
CKD category 5 (%) 34 (22.4) 48 (32.4)
Mean serum bicarbonate (mmol/L)
(SD)
20.6 (2.6) 20.1 (2.5)
Mean haemoglobin (g/L) (SD) 115 (14) 117 (17)
Table 1 Baseline characteristics of randomised participants (n =
300) (Continued)
Sodium bicarbonate
(n = 152)
Placebo
(n = 148)
Mean serum potassium (mmol/L)
(SD)
4.9 (0.5) 4.9 (0.5)
Mean Short physical performance
battery (SD)
8.0 (2.4) 8.1 (2.2)
Mean 6-min walk distance
(m) (SD)
304 (134) 317 (133)
Mean handgrip strength (kg) (SD)
Males 26.6 (8.8) 28.0 (7.6)
Females 15.4 (4.8) 15.8 (4.4)
Mean body mass index (kg/m2)
(SD)
28.9 (4.5) 28.3 (4.6)
Mean mid-arm muscle
circumference (cm) (SD)
24.9 (3.6) 24.8 (4.0)
Mean triceps skinfold
thickness (mm) (SD)
16 (8) 17 (9)
Mean mid-thigh
circumference (cm) (SD)
47.4 (7.0) 46.8 (7.0)
Mean EQ-5D-3L (SD) 0.73 (0.22) 0.74 (0.24)
Mean EQ-5D thermometer (SD) 69 (19) 71 (19)
Mean KDQoL scores
SF36 PCS (SD) 36 (11) 36 (11)
SF36 MCS (SD) 53 (11) 54 (9)
Burden (SD) 75 (26) 75 (25)
Symptoms (SD) 79 (14) 81 (12)
Effects (SD) 86 (14) 87 (15)
Mean office systolic blood
pressure (mmHg) (SD)
143 (18) 143 (18)
Mean office diastolic blood
pressure (mmHg) (SD)
75 (11) 73 (10)
ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor
blocker, CKD chronic kidney disease, KDQOL Kidney Disease Quality of Life
questionnaire, SF-36 Short-Form 36-Item questionnaire, PCS physical
component summary, MCS mental component summary, EQ-5D EuroQoL 5
dimension quality of life questionnaire
*More than one aetiology possible; thus, values sum to > 100%
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at least one timepoint with missing costs in the placebo
group than the bicarbonate group (36% vs 31%). How-
ever, the results were also robust to analyses that used
multiple imputation for missing values.
Discussion
Key findings
Our study is the first to examine the effect of oral bicar-
bonate therapy on physical function, health-related qual-
ity of life and healthcare costs in older people with
advanced CKD. In this trial, administration of oral so-
dium bicarbonate using a dose regime similar to that
currently used in UK practice did not improve physical
function or quality of life, increased adverse events and
had no impact on the rate of progression of CKD com-
pared to placebo in older people with CKD category 4 or
5 and serum bicarbonate concentrations of < 22 mmol/L.
Consistent with these findings, health economic analysis
showed that bicarbonate was less cost-effective than
placebo.
Strengths and weaknesses
Important strengths of this trial were its large size in com-
parison to previous trials in this area, the fact that it
Fig. 2 Serum bicarbonate concentrations. Values are mean and 95% CI
Fig. 3 Subgroup analyses for the primary outcome (Short Physical Performance Battery). Values are mean and 95% CI
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enrolled the age group most likely to suffer the conse-
quences of CKD; clinically relevant follow-up time; par-
ticipant, clinician and researcher masking; and broad
inclusion criteria. In contrast to almost all previous trials,
our use of a placebo control reduced the opportunities for
bias. An additional strength was the broad range of out-
come measures examined, with a particular focus on phys-
ical function and quality of life. These are the outcomes
that older people report being most important to them,
and this focus is of particular importance in this group of
patients with extensive multimorbidity. A narrow focus on
a single disease—even in patients with advanced CKD—
may not be helpful for holistic decision-making; consider-
ing physical function and quality of life enables an assess-
ment of the overall benefit of treatment to patients in a
way that organ-specific measures do not.
A number of limitations require further comment.
Given the modest increase in serum bicarbonate seen
with the dosing schedule used in this trial, it is possible
that larger doses of oral bicarbonate are required to in-
crease serum bicarbonate in older people with CKD, al-
though the mechanisms that might underpin such a
hypothesis are unclear. Whilst such an approach would
be of mechanistic interest, we do not believe that higher
doses (more than the six tablets per day) would be well
tolerated by older people; the adherence rate would
likely be even lower than the moderate adherence rate
observed in the current trial. The higher rate of adverse
events in the bicarbonate arm, particularly gastrointes-
tinal adverse events, slightly lower physical function
measures and lack of a relationship between adherence
and treatment effect size, all argue that a higher dose of
bicarbonate is unlikely to produce health benefits in this
patient group. We cannot exclude a potentially beneficial
effect of bicarbonate in different groups of patients with
CKD, however. In particular, the current trial enrolled
an overwhelmingly white European population. CKD of
Table 2 Secondary outcomes—adjusted treatment effects
(repeated measures analyses using data from all available
timepoints, adjusted for age, sex and CKD category)
Treatment effect (bicarbonate–
placebo) (95% CI)
p
Physical function and
anthropometry
Six-min walk distance (m) − 33 (− 62 to − 4) 0.02
Grip strength (kg) − 1.5 (− 2.8 to − 0.2) 0.03
Weight (kg) 0.2 (− 2.9 to 3.4) 0.89
Mid-arm muscle
circumference (cm)
0.0 (− 0.6 to 0.6) 0.99
Triceps skinfold thickness
(mm)
− 1 (− 2 to 1) 0.34
Mid-thigh circumference
(cm)
0.1 (− 0.8 to 1.1) 0.80
Quality of life
EuroQoL EQ-5D-3L − 0.04 (− 0.08 to 0.00) 0.06
EuroQoL EQ-5D visual
analogue scale
− 3 (− 7 to 1) 0.09
KDQOL symptoms − 1 (− 3 to 2) 0.67
KDQOL burden of disease − 3 (− 8 to 2) 0.20
KDQOL effect of disease − 2 (− 5 to 1) 0.25
KDQOL SF-36 physical com-
ponent summary
− 1 (− 4 to 1) 0.23
KDQOL SF-36 mental com-
ponent summary
− 2 (− 4 to 0) 0.03
Renal biochemistry
Serum bicarbonate (mmol/L) 1.1 (0.6 to 1.6) < 0.001
Serum potassium (mmol/L) 0.0 (− 0.1 to 0.1) 0.80
eGFR (mL/min/1.73 m2)* 0.6 (− 0.8 to 2.0) 0.39
Serum creatinine (umol/L)* − 8 (− 28 to 13) 0.46
Serum cystatin C (mg/L)* − 0.01 (− 0.17 to 0.14) 0.89
Log [urinary albumin/
creatinine ratio]
0.32 (− 0.05 to 0.70) 0.09
Cardiometabolic risk
Log [NT-pro-BNP (pg/mL)] 0.13 (− 0.18 to 0.44) 0.42
Total cholesterol (mmol/L) 0.1 (− 0.2 to 0.3) 0.58
Systolic blood pressure
(mmHg)
0 (− 4 to 3) 0.93
Diastolic blood pressure
(mmHg)
1 (− 1 to 3) 0.16
HbA1c (mmol/mol) 1 (− 1 to 4) 0.38
Bone and mineral metabolism
Log [TRACP-5b (IU/L)] − 0.18 (− 0.43 to 0.08) 0.17
Log [Bs-ALP (μg/L)] 0.01 (− 0.11 to 0.13) 0.83
Log [PTH (pmol/L)] 0.03 (− 0.14 to 0.19) 0.75
Log [25OHD (nmol/L)] − 0.08 (− 0.23 to 0.06) 0.24
1,25OHD (pmol/L) (SD) 3 (− 3 to 9) 0.30
Serum calcium (mmol/L) 0.02 (0.00 to 0.04) 0.11
Table 2 Secondary outcomes—adjusted treatment effects
(repeated measures analyses using data from all available
timepoints, adjusted for age, sex and CKD category) (Continued)
Treatment effect (bicarbonate–
placebo) (95% CI)
p
Serum phosphate (mmol/L) 0.02 (− 0.03 to 0.06) 0.52
Other
Haemoglobin (g/L) − 0.1 (− 0.4 to 0.2) 0.48
Albumin (g/L) 0 (−1 to 1) 0.67
Log [TSH (mIU/L)] 0.07 (− 0.10 to 0.24) 0.39
*Repeated measures analyses using data from all available timepoints,
adjusted for age and sex only
1,25OHD 1,25-dihydroxyvitamin D, 25OHD 25-hydroxyvitamin D, NT-pro-BNP N-
terminal pro B-type natriuretic peptide, Bs-ALP bone-specific alkaline
phosphatase, eGFR estimated glomerular filtration rate, HbA1c glycosylated
haemoglobin, KDQOL kidney disease quality of life, PTH parathyroid hormone,
SF-36 Short-form 36 questionnaire, TRACP-5b tartrate-resistant acid
phosphatase 5b, TSH thyroid-stimulating hormone
The BiCARB study group BMC Medicine           (2020) 18:91 Page 9 of 16
different aetiologies may respond differently and may ex-
plain some of the heterogeneity seen in one recent sys-
tematic review [9, 27].
The original target for recruitment for this trial (380
participants) was not reached despite recruiting from 27
UK sites. This was in part due to a lack of clinical equi-
poise; surveys performed by the trial team during the trial
suggested that most UK nephrologists were treating pa-
tients with serum bicarbonate concentrations < 22mmol/
L with bicarbonate already, thus reducing the pool of eli-
gible participants. It is possible that those most likely to
respond to bicarbonate supplementation were already tak-
ing bicarbonate as part of routine clinical practice, thus
further diluting the effect of the intervention. The dropout
rate in the trial was considerable and slightly higher than
the 10% per 6-month follow-up that we anticipated. Such
a dropout rate is not unexpected given the high levels of
multimorbidity and frailty in this patient population. Al-
though dropout reduces the power of the trial to detect
significant treatment effects, this is mitigated to some ex-
tent by our use of mixed models with repeated measures
for the secondary analyses, which use all available data
and effectively impute missing values. Thus, despite the
lower than planned sample size, and the lower than antici-
pated availability of primary outcome data at 12months,
our results exclude the minimum clinically important im-
provement in the primary outcome with a high degree of
confidence. Some investigators have proposed a smaller
minimum clinically important difference of 0.5 points for
the SPPB [28]; our results also exclude this improvement
with a high degree of confidence. Although the trial was
designed to have adequate power for the primary outcome
and for the EQ-5D outcome, it was not powered to detect
clinically important differences in the rate of deterioration
of renal function, or for rates of commencing dialysis. We
were unable to include the costs of every other medication
used in the cost-effectiveness analysis, which could
potentially lead to over- or underestimation of cost-
effectiveness. Given the higher number of adverse events
in the bicarbonate group (which would be expected to
require additional drugs to treat), it is more likely that
additional medication costs would be higher in the bicar-
bonate arm, further reducing the likelihood that bicarbon-
ate is cost-effective.
Strengths and weaknesses in relation to other studies
Given the association between metabolic acidosis and a
range of adverse outcomes seen in CKD, it would be ex-
pected that amelioration of acidosis (i.e. increasing serum
bicarbonate) could improve physical function, lessen de-
terioration in renal function and improve measures of car-
diovascular health and bone and mineral metabolism in
patients with CKD. A recent systematic review [9] found
no randomised controlled trial evidence around the effect
of bicarbonate on physical function or quality of life; the
current trial therefore provides an important test of the ef-
fect of bicarbonate on these important patient-centred
Table 3 Adverse events by MedDRA System Order Class (SOC)
Bicarbonate
(n = 152)
Placebo
(n = 148)
Number of adverse events per
participant (%)
0 21 (13.8) 16 (10.8)
1 23 (15.1) 41 (27.7)
2 27 (17.8) 35 (23.6)
3 35 (23.0) 15 (10.1)
4 or more 46 (30.3) 41 (27.7)
Total number of adverse events 457 400
SOC classification—number of events
Blood and lymphatic system
disorders
5 1
Cardiac disorders 32 19
Congenital, familial and genetic
disorders
0 1
Ear and labyrinth disorders 1 1
Endocrine disorders 1 2
Eye disorders 6 6
Gastrointestinal disorders 45 25
General disorders and
administration site conditions
14 20
Hepatobiliary disorders 0 0
Immune system disorders 0 0
Infections and infestations 113 118
Injury, poisoning and procedural
complications
41 32
Investigations 5 7
Metabolism and nutrition
disorders
19 27
Musculoskeletal and connective
tissue disorders
28 17
Neoplasms benign, malignant and
unspecified (including cysts
and polyps)
9 16
Nervous system disorders 24 12
Psychiatric disorders 1 5
Renal and urinary disorders 23 23
Reproductive system and breast disorders 4 1
Respiratory, thoracic and
mediastinal disorders
26 14
Skin and subcutaneous tissue disorders 16 11
Surgical and medical procedures 34 30
Vascular disorders 10 12
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Table 4 Adjusted (adjusted for baseline differences (age, gender, stage of CKD, baseline EQ-5D health utility score and baseline
cost)) mean incremental costs, incremental QALYs/outcomes and incremental cost-effectiveness ratio between sodium bicarbonate
vs placebo
Analysis Incremental mean
costs, £ (95% CI)a, b, c
Incremental mean
QALYs/outcomes
(95% CI)a, b, c
Mean incremental
cost-effectiveness ratio
(£/QALY/outcome)
Complete cases over 12-month follow-up (n = 176) 563.74
(88.18 to 1154.18)
−0.047
(− 0.078 to − 0.015)
Dominated
Sensitivity analysis: lower sodium bicarbonate costd 352.76
(− 154.37 to 957.45)
− 0.047
(− 0.078 to − 0.015)
Dominated
Sensitivity analysis: lower inpatient stay coste 539.03
(109.13 to 1050.45)
− 0.046
(− 0.078 to − 0.015)
Dominated
Sensitivity analysis: using ICECAP valuef 636.20
(187.59 to 1189.24)
− 0.017
(− 0.032 to 0.0001)
Dominated
Sensitivity analysis: using life satisfaction valueg 580.19
(143.38 to 1130.11)
− 0.396
(− 0.733 to − 0.059)
Dominated
Complete cases over 24-month follow-up (n = 114)h 591.00
(166.29 to 1078.36)
− 0.083
(− 0.166 to − 0.005)
Dominated
Sensitivity analysis: lower sodium bicarbonate costd 242.59
(− 179.63 to 720.27)
− 0.083
(− 0.166 to − 0.005)
Dominated
Sensitivity analysis: lower inpatient stay coste 593.74
(191.37 to 1072.07)
− 0.083
(− 0.166 to − 0.005)
Dominated
Sensitivity analysis: using ICECAP valuef 598.87
(215.69 to 1052.43)
−0.051
(− 0.095 to − 0.010)
Dominated
Sensitivity analysis: using life satisfaction valueg 682.44
(257.28 to 1142.63)
− 0.974
(− 1.762 to − 0.190)
Dominated
Complete cases over 24-month follow-up and all participants starting
renal replacement therapy during the trial (n = 161)h
808.93
(− 4124.71 to 5411.89)
− 0.074
(− 0.151 to − 0.003)
Dominated
Sensitivity analysis: lower sodium bicarbonate costd 534.61
(− 4385.90 to 5149.69)
− 0.074
(− 0.150 to − 0.003)
Dominated
Sensitivity analysis: lower inpatient stay coste 817.21
(− 4097.90 to 5415.22)
− 0.073
(− 0.151 to − 0.001)
Dominated
Sensitivity analysis: using ICECAP valuef, i 422.08
(− 4091.74 to 4629.60)
− 0.046
(− 0.090 to − 0.002)
Dominated
Sensitivity analysis: lower dialysis costj 600.26
(− 3560.78 to 4379.06)
− 0.075
(− 0.154 to − 0.001)
Dominated
Sensitivity analysis: higher dialysis costk 899.41
(− 4327.11 to 5714.04)
− 0.074
(− 0.156 to 0.002)
Dominated
Sensitivity analysis: using life satisfaction valueg, l 928.18
(− 4373.23 to 5729.68)
− 0.072
(− 1.366 to 0.002)
Dominated
aBootstrapped non-parametric 95% confidence interval (2.5th/97.5th percentile)
bGeneralised linear model with γ distribution and power 0.65 link function to estimate incremental costs and ordinary least squares regression
to estimate incremental QALYs (complete cases)
cGeneralised linear model with Gaussian distribution and power 0.5 link function to estimate incremental costs and ordinary least squares
regression to estimate incremental QALYs (114 complete cases + 47 participants starting renal replacement therapy during the trial with
baseline EQ-5D). For incomplete cases, missing cost data were assumed to be zero and missing EQ-5D data were imputed by carrying forward
the last observation
dApplied average cost of three generic sodium bicarbonate 500mg with the lowest price, £0.14/day
eApplied average of lower quartile unit cost for non-elective inpatient and elective inpatient bed days, £287/day
fAdjusted for baseline differences (age, gender, stage of CKD, baseline ICECAP value and baseline cost)
gAdjusted for baseline differences (age, gender, stage of CKD, baseline life satisfaction value and baseline cost)
hDiscounted at 3.5% per year
iTwo participants from the bicarbonate group without any ICECAP data were excluded from the analysis, n = 159
jApplied average of lower quartile unit cost for haemodialysis (£134/visit) and peritoneal dialysis (£66/visit)
kApplied average of upper quartile unit cost for haemodialysis (£180/visit) and peritoneal dialysis (£77/visit)
lTwo participants (1 from each group) without any life satisfaction data were excluded from the analysis, n = 159
Abbreviations: QALYs quality-adjusted life years, ICER incremental cost-effectiveness ratio, SA sensitivity analysis, ICECAP Investigating Choice
Experiments for the preferences of older people CAPability tool, CKD chronic kidney disease
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outcomes. A previous single-centre trial of bicarbonate
versus usual care found progressive increases in serum bi-
carbonate over a 2-year period in the bicarbonate group;
measures of anthropometry were better in the bicarbonate
group, and fewer participants progressed to end-stage
renal disease in the bicarbonate group (4/67 vs 22/67)
[27]. However, this trial did not use placebo, and thus,
healthcare providers and participants were aware of group
allocation. It is possible that the lack of masking could in-
flate the effect size seen in this trial, perhaps by an impact
on decision-making around renal replacement and on
other treatment decisions driven by knowledge of whether
a participant was receiving bicarbonate. Participants in
this previous trial were recruited from a single centre and
were much younger (mean age 55 years), and a high per-
centage were of south Asian or black origin.
In our trial, oral bicarbonate produced only a modest in-
crease in serum bicarbonate concentration relative to pla-
cebo; this difference was maximal at 3 months and
converged with the placebo group by 24months. Bicar-
bonate concentrations in the placebo group rose gradually
over time, which again limited the contrast between the
two groups; this may be due in part to the pragmatic na-
ture of the trial design, where physicians were free to
switch participants to bicarbonate therapy if this was felt
to be clinically indicated. The effect seen in both recent
systematic reviews [9, 10] was greater than that observed
in the current trial, with a mean 3mmol/L higher serum
bicarbonate in the treatment arm compared to control by
the end of follow-up; restricting analyses to 1-year follow-
up gave similar results. It is likely that the combination of
a modest dose of bicarbonate (in comparison to some
Fig. 4 Scatterplot and cost-effectiveness acceptability curve of incremental cost difference and incremental QALY difference between
randomised groups
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other trials) and suboptimal adherence contributed to this
finding, but as this dosing regimen reflects current UK
practice, patients in the real world are likely to sustain
similarly modest increases in serum bicarbonate concen-
trations. A recent dose-ranging pilot trial (the BASE trial)
suggested that higher dose (approximately 5 g/day) of bi-
carbonate was more effective than lower dose (approxi-
mately 3 g/day) of bicarbonate in increasing serum
bicarbonate concentrations in patients with CKD 3 or 4;
the higher dose provided an additional 1.3-mmol/L in-
crease in mean serum bicarbonate concentration com-
pared to the lower dose [29]. Most trials included in the
systematic review used a ‘treat-to-target’ approach. This
would allow participants with lower bicarbonate concen-
trations to receive higher doses but could also potentially
increase adverse events. Although previous small trials
have used such an approach successfully without evidence
of significant harm [30], harms have not been well re-
ported in bicarbonate trials to date, and our more com-
prehensive approach to adverse event reporting revealed
an excess of events in the bicarbonate arm. Our ability to
titrate doses to the levels used in some previous trials was
limited; we made the decision at the design stage to limit
titration to doubling of the dose at 3 months, which was
performed only if serum bicarbonate concentrations were
still < 22mmol/L. Although this decision was taken to re-
flect the state of usual UK bicarbonate prescribing prac-
tice, practice is heterogeneous and higher doses of
bicarbonate may have greater effects for some patients. In
addition, for participants in the treatment group with only
modest degrees of acidosis, only a small improvement in
serum bicarbonate was required to cross this threshold,
which limited the number of participants for whom a
higher dose of bicarbonate was prescribed.
Although no studies have studied the association between
serum bicarbonate levels and our primary outcome of the
Short Physical Performance Battery, observational data sug-
gest a 7–8% increase in incident functional limitation for
each 1mmol/L lower bicarbonate level in a cohort of older
people, although few of this cohort had CKD [7]. Similarly,
participants in NHANES with a serum bicarbonate concen-
tration < 23mmol/L had a 14% higher risk of low gait speed
for every 1mmol/L lower bicarbonate concentration [6].
These results are not incompatible with our trial results;
larger increases in serum bicarbonate concentration may be
required to produce clinically meaningful changes in phys-
ical performance measures or biochemical parameters such
as bone metabolism markers.
Most trials in the systematic review did not use placebo.
The unmasked nature of these trials is likely to have con-
tributed to the larger treatment effects observed and may
also have influenced decision-making about the com-
mencement of renal replacement therapy in some trials.
Differential dropout is unlikely to explain the small
difference we observed in the current trial as dropout
numbers at each timepoint were similar in each arm. Al-
though adherence was not optimal in the current trial, the
dose of bicarbonate prescribed was similar to that used in
a previous trial [25] that observed greater increases in
serum bicarbonate, and both the dose used and the adher-
ence levels observed in our trial are likely to reflect those
seen in clinical practice, especially amongst older people
taking a large number of medications. A modest difference
in eGFR at both 1 year and at the end of follow-up was
seen in the recent systematic review, although too few
data were available to calculate the mean rate of decline in
eGFR. No significant treatment effect on blood pressure
or body weight was seen in the systematic review, and our
findings are consistent with these observations.
A number of other trials of bicarbonate therapy are cur-
rently in progress or have just been published [31–33].
These trials target a range of severities of CKD (categories
3b to 5), a range of entry serum bicarbonate concentra-
tions and for two of the trials, a strategy of dose adjust-
ment to keep serum bicarbonate > 24mmol/L is
employed. None of these trials targets older people as a
specific group however. The large UBI trial, based in Italy,
randomised 795 individuals with CKD stage 3b or 4 to
usual care or a strategy of bicarbonate treatment to a tar-
get of 24–28mmol/L. The mean dose required to reach
this serum bicarbonate concentration (some 3–4mmol/L
higher than in the usual care arm) was 6 g/day of sodium
bicarbonate—much higher than used in the BiCARB trial.
The UBI trial showed a significant reduction in the rate of
progression of CKD, death and dialysis commencement in
the bicarbonate arm compared to usual care [34]. Patients
in this trial were slightly younger (mean age 67 years) and
had considerably better renal function (mean eGFR of 36
mL/min/1.73 m2), but the trial was not placebo-controlled
or blinded. In contrast, a smaller (n = 149) placebo-
controlled randomised trial in patients with CKD stages 3
and 4 with similar baseline eGFR found a 1–2-mmol/L in-
crease in serum bicarbonate concentration in the treat-
ment arm compared to placebo, using a dose equivalent
to between 2 and 2.5 g per day of sodium bicarbonate
[32]. Similar to the findings of the BiCARB trial, there was
no effect of bicarbonate supplementation on eGFR,
muscle function, blood pressure or quality of life.
Recent trial data suggests that the new hydrochloric
acid binder veverimer can successfully increase serum
bicarbonate concentrations; a mean 3-mmol/L in-
crease compared to placebo was observed over 12
weeks [35]. In addition, veverimer improved disease-
specific quality of life measured using the KDQoL
tool, and improved chair stand time relative to pla-
cebo over 1 year of treatment [36], albeit in a younger
population (mean age 61 years) than studied in the
current trial.
The BiCARB study group BMC Medicine           (2020) 18:91 Page 13 of 16
Conclusions
Implications and future research
Our results suggest that at least for patients aged 60 and
over with CKD GFR categories 4 and 5, 1.5 to 3 g per day
of oral bicarbonate does not produce any health benefits
and may be associated with net harms. Whilst other indica-
tions for control of acidosis exist (for example high potas-
sium concentrations), evidence from the current trial
suggests that the additional cost, treatment burden and side
effects of oral bicarbonate may not justify its use in older
people with advanced CKD and mild degrees of metabolic
acidosis (i.e. serum bicarbonate concentration < 22mmol/
L). Raising bicarbonate levels by an amount sufficient to
produce useful clinical effects will require larger doses than
we used in this trial and is likely to require a ‘treat-to-target’
strategy. However, such doses may not be tolerated by
many older people. Alternative strategies, such as the use of
hydrochloric acid binders, may provide a way round this
issue, but such agents need to be tested against current
practice in representative groups of patients, using a range
of outcomes relevant to older people including physical
function, quality of life and deterioration of renal function.
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